News and Announcements
PromarkerD Shows Improved Predictive Ability & Robustness
- Published December 15, 2016 3:19PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Proteomics International Laboratories Ltd (ASX: PIQ) is pleased to provide an update on its clinical studies for PromarkerD, the company’s breakthrough test for the prediction of diabetic kidney disease.
Highlights:
- PromarkerD predicts diabetic kidney disease across all major clinical definitions of rapid decline in kidney function
- Predictive ability improved – PromarkerD correctly predicted 61-97% of individuals who went on to have a clinically significant decline in kidney function within four years
- Inter-laboratory study shows robustness of PromarkerD as a future Laboratory Developed Test
There are currently 415 million adults worldwide with diabetes, and approximately one third of these people have chronic kidney disease which can lead to dialysis or kidney transplant.
To read the full announcements please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
